OPRX logo

OPRXOptimizeRx Corp

$5.48
$0.29
(5.59%)
Today
Updated: 02:01 PM EDT
Reported EarningsMay 12
Mkt Cap$97.39M
Vol223,611.00
News
all
press releases
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressures near-term growth.
Zacks
News Placeholder
More News
News Placeholder
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.
Zacks
News Placeholder
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.
Zacks
News Placeholder
OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?
OPRX cuts 2026 revenue view to $95-$100M as MFN pricing disruption and macro uncertainty squeeze budgets - will pressures ease?
Zacks
News Placeholder
OptimizeRx (OPRX) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
News Placeholder
OptimizeRx Corp. (OPRX) Surpasses Q1 Earnings and Revenue Estimates
OptimizeRx (OPRX) delivered earnings and revenue surprises of +1,300.00% and +7.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
OptimizeRx Expands EHR Advertising Reach With New DSP Integration
OPRX launched a programmatic EHR ad connection for DSPs, expanding point-of-care targeting and access to authenticated inventory.
Zacks
News Placeholder
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.
Zacks
News Placeholder
OptimizeRx (NASDAQ:OPRX) Lowered to "Hold" Rating by Zacks Research
Zacks Research lowered OptimizeRx from a "strong-buy" rating to a "hold" rating in a report on Monday...
MarketBeat
News Placeholder
OptimizeRx (OPRX) Projected to Post Earnings on Tuesday
OptimizeRx (NASDAQ:OPRX) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at...
MarketBeat
<
1
2
...
>